Carregant...
Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies
Vancomycin-resistant enterococci (VRE) are a leading cause of nosocomial infections due to the limited number of effective therapeutic options. In an effort to repurpose FDA-approved drugs against antibiotic-resistant bacteria, we identified auranofin as a potent drug against VRE. The present study...
Guardat en:
| Publicat a: | Int J Antimicrob Agents |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7073294/ https://ncbi.nlm.nih.gov/pubmed/31669742 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijantimicag.2019.10.009 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|